Sat Feb 01 21:35:00 IST 2025: ## New Urine Test Shows Promise for Prostate Cancer Screening

**Ann Arbor, MI – February 1, 2025** – A new urine test, MyProstateScore 2.0 (MPS2), offers a less invasive and more cost-effective alternative to traditional prostate cancer screening methods, according to a new study published today. Researchers at the University of Michigan Health Rogel Cancer Center clinically validated the test, demonstrating its ability to accurately identify men at high risk of aggressive prostate cancer without the need for uncomfortable and potentially unnecessary procedures like digital rectal exams and biopsies.

The MPS2 test analyzes 18 genes linked to high-grade prostate cancer. In a study of 266 men, the test accurately detected 94% of cancers classified as Gleason Grade Group 2 or higher—those most likely to be aggressive and require treatment. This compares favorably to the sensitivity of traditional blood tests. Furthermore, mathematical modeling suggests that widespread use of MPS2 could prevent up to 53% of unnecessary biopsies.

Unlike traditional methods that often lead to overdiagnosis of low-grade cancers, MPS2 focuses on identifying aggressive forms of the disease. This allows patients and physicians to make informed decisions, avoiding unnecessary anxiety and healthcare expenses associated with more invasive procedures and follow-up care.

“These results show that MPS2 has promise as an at-home test,” said Ganesh S. Palapattu, a co-author of the study. “Its primary benefit is that the test can accurately predict your probability of developing aggressive prostate cancer, putting both the patient and physician at ease.” The researchers are now planning further studies to evaluate the test’s effectiveness as a surveillance tool for low-risk prostate cancer. The lower cost compared to MRIs also makes MPS2 a financially attractive alternative.

Read More